Physician profile
Gerardo Lopez
NPI 1720084031
$1,928.15
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $554 · 2021: $633 · 2022: $37.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $404.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $348.97 | 2020-2021 | |
| Tris Pharma INC | $302.45 | 2019-2021 | |
| Adlon Therapeutics L.P. | $171.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $162.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.83 | 2020-2021 | |
| Neos Therapeutics, LP | $104.05 | 2019-2021 | |
| Pfizer INC. | $82.51 | 2019-2021 | |
| Glaxosmithkline, LLC. | $80.18 | 2019-2021 | |
| Kaleo, INC. | $73.29 | 2019-2021 | |
| Novo Nordisk INC | $37.51 | 2022 | |
| Sanofi Pasteur INC. | $26.46 | 2021 | |
| Sobi, INC | $16.23 | 2019 | |
| Phadia US INC. | $11.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.